DLX1 and ovarian cancer: DLX1 hosts enhanced MYCN binding, predominantly enriched across a DNA stretch of ~1 kb that flanks its TSS and encompasses the core promoter, as well as TFBSs for FOXM1 that were previously characterized in ovarian cancer [74] (Figure 2A upper panel).